- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01973374
Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy (Sugar Text)
February 19, 2015 updated by: Celeste Durnwald, University of Pennsylvania
Maternal diabetes in pregnancy can negatively impact fetal well-being and contribute to adverse pregnancy outcomes.
Much of the morbidity associated with diabetes in pregnancy can be minimized with tight glucose control.
A number of studies in non-pregnant populations have highlighted the feasibility, acceptability and efficacy of text messaging interventions for improving diabetic compliance and control.
This study will investigate whether a text messaging intervention is feasible and effective in an urban, diabetic, obstetric clinic and whether this intervention can improve compliance with diabetes care, glucose control and pregnancy outcomes.
The study will also assess satisfaction with the intervention itself.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Pregnant women aged 18-50 years
- Planned delivery at Hospital of the University of Pennsylvania
Exclusion Criteria:
- Gestational age greater than 34 weeks at initial visit in the Penn Perinatal Diabetes Program
- Women who are unable to read English as all text messages will be in English
- Women who do not have a cellular phone capable of receiving text messages as this is the study intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Routine Care
|
|
|
Experimental: Text Message Intervention
The text message intervention group receives usual prenatal and diabetic care in addition to two text messages per week throughout the pregnancy and a reminder text message prior to the postpartum visit.
The text message intervention group also fills out a survey about the intervention after delivery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Satisfaction
Time Frame: date of enrollment up to 12 weeks post partum
|
Patient satisfaction with the texting intervention as measured by a post-study survey
|
date of enrollment up to 12 weeks post partum
|
|
Compliance with Obstetric and Diabetes Care
Time Frame: OB screening visit through 12 weeks postpartum
|
Proportion of prenatal visits attended, proportion of assigned blood glucose logs sent to clinic for review, proportion of assigned blood glucose values checked, compliance with attendance at postpartum visit.
|
OB screening visit through 12 weeks postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy measures
Time Frame: Diabetes diagnosis through 12 weeks postpartum
|
Measuring the proportion of blood glucose values within the target range each week; mean fasting and postprandial blood glucose values measured weekly; change in hemoglobin A1C (for pregestational diabetics) from initiation of care to the third trimester
|
Diabetes diagnosis through 12 weeks postpartum
|
|
Healthcare Utilization Measures
Time Frame: Screening OB visit through 12 weeks postpartum
|
Measuring the number of visits to the perinatal evaluation center related to diabetes care and the total number of antepartum hospitalizations.
|
Screening OB visit through 12 weeks postpartum
|
|
Maternal Outcomes
Time Frame: Delivery date through 12 weeks postpartum
|
Measuring the mode of delivery (spontaneous vaginal, operative vaginal, cesarean section), complications of delivery (shoulder dystocia, postpartum hemorrhage, third and fourth degree lacerations), and length of hospital stay.
|
Delivery date through 12 weeks postpartum
|
|
Neonatal Outcomes
Time Frame: Neonate delivery through 12 weeks postpartum
|
Measuring fetal demise; neonatal death; birthweight; large for gestational age; small for gestational age; APGAR scores; umbilical cord blood gas; NICU admission; respiratory distress; hypoglycemia; hyperbilirubinemia; length of hospital stay
|
Neonate delivery through 12 weeks postpartum
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
April 1, 2014
Study Registration Dates
First Submitted
October 24, 2013
First Submitted That Met QC Criteria
October 24, 2013
First Posted (Estimate)
October 31, 2013
Study Record Updates
Last Update Posted (Estimate)
February 20, 2015
Last Update Submitted That Met QC Criteria
February 19, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 817181
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
Royal College of Surgeons, IrelandHealth Research Board - Trials Methodology Research NetworkCompletedPre-Gestational DiabetesIreland
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
University of Tennessee Graduate School of MedicineRecruitingInsulin Resistance | Pregnancy Complications | Pregnancy | Preeclampsia | Gestational Diabetes | Gestational Diabetes Mellitus in Pregnancy | Placental Dysfunction | Gestational Diabetes Mellitus (GDM) | Preeclampsia (PE) | Cardiometabolic Diseases | Gestational Complications | Preeclampsia (PE) RiskUnited States
-
Woman'sBaton Rouge Area FoundationCompletedGestational Diabetes MellitusUnited States
-
Lahore University of Biological and Applied SciencesNot yet recruitingPregnancy Complications | Gestational Diabetes Mellitus (GDM) | Diabetes During Pregnancy | Pregnancy in Diabetes | Gestational | Diabetes ComplicationPakistan
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
Clinical Trials on Text Message Intervention
-
Dokuz Eylul UniversityActive, not recruitingType 2 Diabetes Mellitus (T2DM) | Patient Activation | Diabetes Self-management | Diabetes Mellitus (DM)Turkey
-
Massachusetts General HospitalCompletedHypertension | Type2 Diabetes | HyperlipemiaUnited States
-
Samanta Winck MadrugaUnknown
-
Boston UniversityCompletedEating DisordersUnited States
-
Emory UniversityNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
Massachusetts General HospitalCompletedAcute Coronary SyndromeUnited States
-
Universidad Peruana Cayetano HerediaCompleted
-
University of PennsylvaniaCompletedColonoscopy | Adherence, Patient | Text MessagingUnited States
-
St. Louis UniversityEpharmix, Inc.TerminatedShort Bowel SyndromeUnited States
-
Boston Medical CenterCompletedAmbulation DifficultyUnited States